semaglutide canada patent expiry Novo Nordisk lets Canadian expire As the patent for semaglutide,

Here we present a case of AP in a diabetic patient who recently started on subcutaneous semaglutide for glycemic control

Low Blood Sugar (Hypoglycemia): While semaglutide rarely causes low blood sugar on its own, the risk increases if you take it alongside insulin or sulfonylureas

GLP-1 peptides influence key metabolic pathways that regulate hunger, digestion, and blood sugar balance

Common effects include: Dry mouth Insomnia Increased heart rate Nervousness or restlessness Mild blood pressure elevation Best practices include early dosing, hydration, stimulant avoidance, and regular monitoring of blood pressure and heart rate